Prostaglandin E1 nanoparticle - LTT Bio-Pharma

Drug Profile

Prostaglandin E1 nanoparticle - LTT Bio-Pharma

Alternative Names: LT-0101; Nano prostaglandin E1; Nano-PGE1

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LTT Bio-Pharma
  • Class Prostaglandins
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Intermittent claudication; Spinal stenosis
  • No development reported Arterial occlusive disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Arterial-occlusive-disorders in Japan (IV)
  • 14 Aug 2015 LTT Bio-Pharma has international patent protection for nanoparticles for drug delivery
  • 10 May 2010 Early research in Arterial occlusive disorders in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top